Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
These sessions showcase case studies over dual compartment disease and immunotherapy vs. chemotherapy. These sessions are presented by:R. Taylor Ripley, MD, Baylor College of MedicineManish
Surgery is vital option for treatment for many patients with pleural mesothelioma. This session discusses how pleural surgery works and why it is an option
Mesothelioma treatments are diverse. When a patient sees their oncologist, they may hear differing treatment options. These sessions focus on the different tools for treatment
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
